Company newsForm 8-K and release
Summit Therapeutics SMMT
Summit Therapeutics says FDA issued a complete response letter for ivonescimab
The company says the FDA determined the application cannot be approved in its present form without a statistically significant overall survival improvement.
GetSignal
On November 15, 2026, Summit Therapeutics said the U.S. Food and Drug Administration issued a complete response letter for its biologics license application for ivonescimab, given with platinum-containing chemotherapy, for patients with locally advanced or metastatic non-small cell lung cancer who have received prior EGFR tyrosine kinase inhibitor therapy. The company said the letter indicates the application cannot be approved in its present form.
According to the company, the FDA determined that substantial evidence of effectiveness is not established without a statistically significant overall survival improvement. The company said the FDA indicated that the progression-free survival benefit, without a statistically significant overall survival benefit, does not support a positive benefit-risk profile in support of approval. The company said there are currently no FDA-approved regimens that have demonstrated a statistically significant overall survival benefit in this patient setting.
The company said the primary overall survival analysis for ivonescimab with chemotherapy showed a positive trend without achieving a statistically significant result. In a post-hoc analysis, longer-term follow-up of western patients showed a consistent overall survival benefit across regions, with a hazard ratio of 0.76 in the full population, Asian patients and western patients.
The application was supported by the HARMONi study, a global, randomized, double-blind Phase III clinical trial. The company said HARMONi met its progression-free survival primary endpoint, and that ivonescimab with chemotherapy showed an acceptable and manageable safety profile consistent with previous studies. Ivonescimab is not approved by any regulatory authority in the company's license territories, including the United States and Europe.
Robert W. Duggan, Chairman and Co-Chief Executive Officer, said the company is disappointed for patients and their families awaiting additional treatment options in this setting. Duggan said Summit Therapeutics would continue its clinical development program for ivonescimab.
Key facts
- Announced
- November 15, 2026
- Regulatory action
- Complete response letter
- Application
- Biologics license application for ivonescimab
- Patient setting
- Locally advanced or metastatic non-small cell lung cancer after prior EGFR TKI therapy
- Post-hoc overall survival hazard ratio, full population
- 0.76
Sources: Form 8-K filed November 16, 2026, and the company's release on Business Wire, November 15, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
Summit Therapeutics first, then the newest- Summit Therapeutics to feature ivonescimab data at ESMO 2026
SMMT · Summit Therapeutics · Company release · Oct 22, 2026
- Summit Therapeutics enters ivonescimab trial collaboration with ECOG-ACRIN
SMMT · Summit Therapeutics · Company release · Oct 21, 2026
- Summit Therapeutics opens global Phase II ivonescimab study in kidney cancer
SMMT · Summit Therapeutics · Company release · Oct 19, 2026
- Canadian Natural Resources agrees to acquire Advantage Energy
CNQ · Canadian Natural Resources · Company release · Nov 16, 2026
- Rio Tinto, BCL and ABG agree to establish fund for Panguna mine legacy impacts
RIO · Rio Tinto Group · Company release · Nov 16, 2026
- Viking Therapeutics shares VK2735 obesity trial analysis at ObesityWeek 2026
VKTX · Viking Therapeutics · Company release · Nov 15, 2026
